Your browser doesn't support javascript.
loading
Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature.
Watanabe, Tsubasa; Firat, Elke; Scholber, Jutta; Gaedicke, Simone; Heinrich, Corinne; Luo, Ren; Ehrat, Nicolas; Multhoff, Gabriele; Schmitt-Graeff, Annette; Grosu, Anca-Ligia; Abdollahi, Amir; Hassel, Jessica C; von Bubnoff, Dagmar; Meiss, Frank; Niedermann, Gabriele.
Afiliação
  • Watanabe T; Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Robert-Koch-Strasse 3, 79106, Freiburg, Germany.
  • Firat E; Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan.
  • Scholber J; Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Robert-Koch-Strasse 3, 79106, Freiburg, Germany.
  • Gaedicke S; Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Robert-Koch-Strasse 3, 79106, Freiburg, Germany.
  • Heinrich C; Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Robert-Koch-Strasse 3, 79106, Freiburg, Germany.
  • Luo R; Department of Dermatology and Venerology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Ehrat N; Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Robert-Koch-Strasse 3, 79106, Freiburg, Germany.
  • Multhoff G; Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • Schmitt-Graeff A; Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Robert-Koch-Strasse 3, 79106, Freiburg, Germany.
  • Grosu AL; Department of Radiation Oncology, Technical University Munich, Munich, Germany.
  • Abdollahi A; German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center, Heidelberg, Germany.
  • Hassel JC; Institute of Pathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • von Bubnoff D; Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Robert-Koch-Strasse 3, 79106, Freiburg, Germany.
  • Meiss F; German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center, Heidelberg, Germany.
  • Niedermann G; Department of Radiation Oncology, Heidelberg University Medical School, Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCOR), Heidelberg, Germany.
Cancer Immunol Immunother ; 69(9): 1823-1832, 2020 Sep.
Article em En | MEDLINE | ID: mdl-32350591
ABSTRACT
Radiotherapy can elicit abscopal effects in non-irradiated metastases, particularly under immune checkpoint blockade (ICB). We report on two elderly patients with oligometastatic melanoma treated with anti-PD-1 and stereotactic body radiation therapy (SBRT). Before treatment, patient 1 showed strong tumor infiltration with exhausted CD8+ T cells and high expression of T cell-attracting chemokines. This patient rapidly mounted a complete response, now ongoing for more than 4.5 years. Patient 2 exhibited low CD8+ T cell infiltration and high expression of immunosuppressive arginase. After the first SBRT, his non-irradiated metastases did not regress and new metastases occurred although neoepitope-specific and differentiation antigen-specific CD8+ T cells were detected in the blood. A second SBRT after 10 months on anti-PD-1 induced a radiologic complete response correlating with an increase in activated PD-1-expressing CD8 T cells. Apart from a new lung lesion, which was also irradiated, this deep abscopal response lasted for more than 2.5 years. However, thereafter, his disease progressed and the activated PD-1-expressing CD8 T cells dropped. Our data suggest that oligometastatic patients, where a large proportion of the tumor mass can be irradiated, are good candidates to improve ICB responses by RT, even in the case of an unfavorable pretreatment immune signature, after progression on anti-PD-1, and despite advanced age. Besides repeated irradiation, T cell epitope-based immunotherapies (e.g., vaccination) may prolong antitumor responses even in patients with unfavorable pretreatment immune signature.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor de Morte Celular Programada 1 / Melanoma Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor de Morte Celular Programada 1 / Melanoma Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article